To assess the efficacy and safety of using recombinant humanized anti-CD25 monoclonal antibody injection as a prophylactic strategy for reducing the incidence of severe acute graft-versus-host disease (aGVHD) in adult patients at intermediate to high risk, as predicted by the dynamic aGVHD Onset Anticipation Tianjin (daGOAT) model, following allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Age ≥ 16 years, regardless of gender.
Patients with hematologic disorders who are scheduled to receive allo-HSCT.
Voluntarily join this study, sign the informed consent form, have good compliance, and be willing to cooperate with follow-up.
Patients who have received a second or multiple transplants.
Patients who are allergic to, or intolerant of, a recombinant humanized anti-CD25 monoclonal antibody injection.
Pregnant or lactating female patients or female patients who are unable to take effective contraceptive measures during the entire trial period.